Accelerating cell movement to improve the speed and quality of healing after tissue damage is only part of the therapeutic potential of modulated cell motility. MicroCures also believes that slowing or stopping cells from moving altogether can in certain contexts – such as cancer metastasis or fibrosis – play a significant therapeutic role.
To this end, the company is advancing a therapeutic program focused on silencing the activity of the key microtubule regulatory proteins (MRPs) that stimulate cell motility. These MRPs, which include kinesin-like protein KlF19 and centrosomal protein Cep192, have been demonstrated to contribute to cellular activity that is believed to influence the movement of cancer cells, as well as the development of fibrosis.
MicroCures is currently conducting early-stage studies designed to support the development of siRNA-based therapeutics capable of silencing KlF19 and Cep192. Ultimately, the company believes that these compounds may have therapeutic applications for combatting cancer metastasis and preventing or reducing fibrosis.